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Abstract The molecular species compositions of monoacyl-
glycerols obtained from various rat tissues were examined by
reverse-phase high-performance liquid chromatography (HPLC)
and gas chromatography-mass spectrometry (GC-MS) analyses.
We confirmed that 2-arachidonoylglycerol, an endogenous
cannabinoid receptor agonist, is one of the most abundant
molecular species of monoacylglycerols in the brain. Substantial
amounts of 2-arachidonoylglycerol were also found in the liver,
spleen, lung and kidney, but the levels were considerably lower
than that in the brain. We found that a small amount of
2-arachidonoylglycerol was generated in a brain homogenate
during incubation in the absence of Ca2+. Importantly, the
generation of 2-arachidonoylglycerol was markedly augmented
in the presence of Ca2+, suggesting that Ca2+ plays a key role in
regulation of the generation of 2-arachidonoylglycerol in this
tissue.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
v9-Tetrahydrocannabinol is a psychoactive constituent of
marijuana, and is known to exert a variety of biological e¡ects
in experimental animals and man, although its mechanisms of
action remained unclear until recently. A decade ago, Devane
et al. [1] demonstrated the presence of a speci¢c binding site
for cannabinoids in rat brain synaptosomes. Soon after, Mat-
suda et al. [2] cloned the cDNA for the cannabinoid CB1
receptor from a rat brain cDNA library. These ¢ndings con-
stitute evidence that the actions of cannabinoids are mediated
largely through speci¢c receptor(s), and suggested the occur-
rence of an endogenous cannabinoid receptor ligand(s). Evans
et al. [3] demonstrated that (a) material(s) having the ability to
bind to the cannabinoid receptor is released from A23187-
stimulated rat brain slices, although its chemical structure
has not yet been elucidated. In 1992, an endogenous canna-
binoid receptor ligand, named anandamide, was isolated from
pig brain by Devane et al. [4]. This compound has been shown
to exhibit various cannabimimetic activities in vitro and in
vivo [5]. However, the levels of anandamide in various living
tissues were found to be very low [6^10]. Furthermore, the
biosynthetic pathways for anandamide (N-acylphosphatidyl-
ethanolamine pathway [7,8,11,12] and the condensation path-
way [8,13^15]) do not appear to be able to provide a large
amount of anandamide, at least under normal conditions.
These observations raised the possibility that another type
of endogenous cannabinoid receptor ligand may exist.
In 1995, we [16], and Mechoulam et al. [17] proposed that
2-arachidonoylglycerol is another type of endogenous ligand
for the cannabinoid receptor(s). We obtained evidence that
2-arachidonoylglycerol exhibits binding activity toward the
cannabinoid receptor in rat brain synaptosomes [16], and
that 2-arachidonoylglycerol induces rapid elevation of the in-
tracellular free Ca2 concentration through the cannabinoid
CB1 receptor on NG108-15 cells [18,19], and suggested that
the cannabinoid CB1 receptor is originally a 2-arachidonoyl-
glycerol receptor [18^20]. Mechoulam et al. [17] demonstrated
that 2-arachidonoylglycerol binds to either CB1 or CB2 re-
ceptors, and inhibits adenylate cyclase in spleen cells and the
twitch response in the mouse vas deferens. Furthermore, re-
cently Stella et al. [21] reported that 2-arachidonoylglycerol
inhibits long-term potentiation (LTP) in the rat hippocampus
via a cannabinoid CB1 receptor-dependent mechanism.
Nevertheless, not much is known concerning the tissue levels
of 2-arachidonoylglycerol. Mechoulam et al. [17] detected
2-arachidonoylglycerol in canine gut, yet the exact tissue level
is not known. We detected 3.3 nmol of arachidonoylglycerol
[16], and Stella et al. [21] detected 4.0 nmol/g tissue of
2-arachidonoylglycerol in rat brain. However, little informa-
tion is so far available concerning the tissue levels of mono-
acylglycerols, especially those containing arachidonic acid, ex-
cept in the case of brain. Furthermore, it has not yet been
established whether or not mammalian tissues actually con-
tain both enzyme activities and the substrates for the gener-
ation of substantial amounts of 2-arachidonoylglycerol.
In this study, we developed a new method for the quanti¢-
cation of monoacylglycerols. We found that various tissues
other than blood plasma contain signi¢cant amounts of
2-arachidonoylglycerol besides other species of monoacylglyc-
erols, and that a large amount of 2-arachidonoylglycerol is
produced in a rat brain homogenate upon incubation.
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2. Materials and methods
2.1. Chemicals
1(3)-Myristoylglycerol, 1(3)-palmitoylglycerol, 2-palmitoylglycerol,
1(3)-stearoylglycerol, 1(3)-oleoylglycerol, 1(3)-eicosaenoylglycerol and
various types of fatty acids were obtained from Sigma (St. Louis, MO,
USA). 1(3)-Linoleoylglycerol was purchased from Doosan Serdary
Res. Lab. (Englewood Cli¡s, NJ, USA). 1-Anthroyl cyanide, diiso-
propyl£uorophosphate (DFP), N-tris(hydroxymethyl)methyl-2-amino-
ethanesulfonic acid (TES), and butylated hydroxytoluene (BHT) were
obtained from Wako Pure Chem. Ind. (Osaka, Japan). Quinuclidine
was from Molecular Probes, Inc. (Eugene, OR, USA). Various types
of 2-monoacylglycerol were prepared as described previously [18].
1(3)-Palmitoylglycerol, 1(3)-cis-vaccenoylglycerol, 1(3)-arachidonoyl-
glycerol, and 1(3)-docosahexaenoylglycerol were synthesized from ap-
propriate fatty acid anhydrides and glycerol, and then puri¢ed by
borate-impregnated thin-layer chromatography (TLC).
2.2. HPLC analysis of monoacylglycerols
Various species of standard monoacylglycerols were converted to
dianthroyl derivatives as described previously [19]. Brie£y, monoacyl-
glycerols were treated with 1-anthroyl cyanide (0.2 mg) in 200 Wl of
dehydrated acetone containing 0.08% quinuclidine at 45‡C for 60 min.
The reaction was stopped by the addition of 50 Wl of methanol. The
resultant dianthroyl derivatives of monoacylglycerol were puri¢ed by
TLC and developed with petroleum ether/diethyl ether/acetic acid
(65:35:1, v/v). The puri¢ed dianthroyl derivatives of monoacylglycer-
ols were analyzed with a HPLC system equipped with a reverse phase
column (Shiseido; CAPCELL PAK C18 SG, 4.6U250 mm), and a
£uorescence detector (excitation at 370 nm; emission at 470 nm) as
described previously [19].
2.3. Extraction and puri¢cation of monoacylglycerols from various rat
tissues
Various organs were taken from male Wistar rats (200^280 g body
weight). Blood was taken by means of cardiac puncture using heparin
as an anticoagulant, and platelet-poor plasma was separated by cen-
trifugation. Total lipids were extracted by the method of Bligh and
Dyer [22]. BHT (¢nal, 0.05%) was added to avoid lipid peroxidation.
Monoacylglycerol was puri¢ed and analyzed as described previously
[19]. Brie£y, a portion of the total lipids (equivalent to 1 g or 0.5 g wet
tissue), with 1 nmol of 2-heptadecanoylglycerol added as an internal
standard, was fractionated by TLC and developed with petroleum
ether/diethyl ether/acetic acid (20:80:1, v/v) in a tank sealed with
N2 gas. The area corresponding to standard monoacylglycerol was
scraped o¡ the TLC plate, followed by extraction from the silica gel
by the method of Bligh and Dyer. The extraction was conducted in
the presence of BHT (0.001%) in an N2 gas-sealed tube. Monoacyl-
glycerols were further puri¢ed by TLC and developed with petroleum
ether/diethyl ether/acetic acid (20:80:1, v/v). The puri¢ed monoacyl-
glycerols were converted to their 1-anthroyl derivatives and then an-
alyzed as described above.
2.4. GC-MS analysis of trimethylsilyl (TMS) derivatives of
monoacylglycerols obtained from rat brain
Monoacylglycerols obtained from rat brain (total 23 g) were
puri¢ed by silicic acid column chromatography, and then by TLC
and developed with petroleum ether/diethyl ether/acetic acid
(20:80:1, v/v). Monoacylglycerols were further puri¢ed by TLC and
developed with the same solvent system twice. The puri¢ed mono-
acylglycerols were converted to TMS derivatives by treatment with
N,O-bis-tri£uorotrimethylsilylacetamide (Wako Pure Chem. Ind.,
Osaka, Japan) at 30‡C for 30 min. The resultant TMS derivatives
of monoacylglycerols were then subjected to GC-MS analysis. Elec-
tron impact (70 eV) mass spectra of TMS derivatives of the mono-
acylglycerols were obtained using a JEOL JMS-SX102A mass spec-
trometer (accelerating voltage, 10 kV; ionizing current, 300 WA)
coupled with a gas chromatograph equipped with a fused silica col-
umn (JpW Scienti¢c, DB-1701, 30 mU0.25 mm I.D., 0.25 Wm thick-
ness). The column temperature was increased from 200‡C to 280‡C at
the rate of 10‡C/min. The temperature for the injection port, interface
and ion source was 250‡C, respectively.
2.5. Generation of 2-arachidonoylglycerol in a rat brain homogenate
Brains were taken from Wistar male rats immediately after decap-
itation. The brains were homogenized in 10 volumes of 0.32 M su-
crose/5 mM TES bu¡er (pH 7.4) containing 0.5 mM EDTA and 1 mM
DFP using a Potter-Elvehjem glass-Te£on homogenizer. The protein
content was determined by the method of Lowry et al. [23]. Each
brain homogenate was diluted with 12 volumes of 20 mM TES bu¡er
(pH 7.4) containing 122 mM NaCl, 3.1 mM KCl, 0.4 mM KH2PO4,
1 mM NaHCO3, 1.2 mM MgSO4, 1.3 mM CaCl2, 10 mM glucose and
1 mM DFP, which was added to block monoacylglycerol lipase
activity, to a ¢nal concentration of 5 mg protein/5 ml, followed by
incubation at 37‡C for 5 min. In some cases, 2.5 mM EGTA was
added instead of 1.3 mM CaCl2. After the incubation, the reaction
was stopped by the addition of chloroform and methanol. Total lipids
were extracted by the method of Bligh and Dyer, and monoacylglyc-
erols were puri¢ed and analyzed as dianthroyl derivatives using
2-heptadecanoylglycerol as an internal standard as described above.
3. Results
We developed a new method for the separation of various
species of dianthroyl derivatives of monoacylglycerols on re-
verse-phase HPLC. Various species of 1(3)-monoacylglycerols
and 2-monoacylglycerols were separated well from each other
with this HPLC method, although the separation of myristic
acid-containing and palmitoleic acid-containing species, and
that of palmitic acid-containing and oleic acid- or cis-vaccenic
acid-containing species were not satisfactory, at least under
the present experimental conditions (data not shown). We
con¢rmed that the £uorescence intensity increased almost lin-
early, at least from 10 pmol to 3 nmol of 1(3)- or 2-mono-
acylglycerols (data not shown). We also con¢rmed that the
£uorescence intensities of the same amounts of dianthroyl
derivatives of 2-arachidonoylglycerol, 1(3)-arachidonoyl-
glycerol, 2-palmitoylglycerol and 1(3)-palmitoylglycerol were
not so di¡erent, at least in the range described above (data
not shown). Employing this novel analytical method, we de-
termined the levels of monoacylglycerols in various rat tissues.
Table 1 summarizes the results of such analyses. We found
that various rat tissues contain substantial amounts of mono-
acylglycerols. The highest value was noted in brain. Notice-
ably, brain contains a high amount of 2-arachidonoylglycerol
besides a lower amount of 1(3)-arachidonoylglycerol, the level
of total arachidonoylglycerol being 4.75 nmol/g tissue and
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Fig. 1. Mass chromatograms ([M]) of TMS derivatives of mono-
acylglycerols obtained from rat brain by GC-MS. A: Total ion. B:
m/z 522 (2-arachidonoylglycerol (retention time, 10.59 min) and
1(3)-arachidonoylglycerol (retention time, 11.11 min)). C: m/z 500
(2-oleoylglycerol (retention time, 9.03 min), 2-cis-vaccenoylglycerol
(retention time, 9.14 min), 1(3)-oleoylglycerol (retention time, 9.38
min), and 1(3)-cis-vaccenoylglycerol (retention time, 9.46 min)). D:
m/z 474 (2-palmitoylglycerol (retention time, 7.65 min) and 1(3)-pal-
mitoylglycerol (retention time, 7.91 min)).
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accounting for 44.1% of the total monoacylglycerols. Other
tissues, such as liver, spleen, lung and kidney, also contain
substantial amounts of arachidonoylglycerols. However, the
amounts of arachidonoylglycerols (nmol/g tissue) in these tis-
sues were markedly lower than those in brain, being about
29^38% of those in brain. The relative proportions of arach-
idonoyl species in the total monoacylglycerols in these tissues
(17^27% of total monoacylglycerols) were also considerably
lower than those in brain. We also found that substantial
amounts of monoacylglycerols are present in blood plasma.
The levels of arachidonoylglycerols in blood plasma were,
however, very low, which is quite di¡erent from the levels in
other tissues.
The structures of monoacylglycerols in brain were further
examined by GC-MS analyses, because the separation of pal-
mitic acid-containing, oleic acid-containing, and cis-vaccenic
acid-containing species was not successful on HPLC analyses
(Table 1). Fig. 1 illustrates mass chromatograms ([M]) of
TMS derivatives of monoacylglycerols obtained from rat
brain. We obtained evidence that rat brain actually contains
2-palmitoylglycerol, 1(3)-palmitoylglycerol, 2-oleoylglycerol,
1(3)-oleoylglycerol, 2-cis-vaccenoylglycerol and 1(3)-cis-vacce-
noylglycerol besides 2-arachidonoylglycerol and 1(3)-arach-
idonoylglycerol. The electron impact mass spectra of TMS-
derivative of arachidonoylglycerols in brain are shown
in Fig. 2. Fig. 2A: 2-arachidonoylglycerol (m/z 522 for
[M], m/z 507 for [M-CH3], m/z 451 for [M-71], m/z 432
for [M-TMSOH], m/z 218 for [M-RCOOH]) ; Fig. 2B:
1(3)-arachidonoylglycerol (m/z 522 for [M], m/z 507 for
[M-CH3], m/z 432 for [M-TMSOH], m/z 419 for [M-
TMSOCH2]).
Finally, we examined whether or not 2-arachidonoylglycer-
ol is generated in a rat brain homogenate. As shown in Fig.
3A, we found that a large amount of 2-arachidonoylglycerol
was generated in a rat brain homogenate when it was incu-
bated in the presence of Ca2 at 37‡C for 5 min (6.4-fold and
98.5 pmol/mg protein increases over the level at time 0). We
also found that substantial amounts of 2-palmitoylglycerol
plus 2-oleoylglycerol plus 2-cis-vaccenoylglycerol (Fig. 3C),
and 1(3)-palmitoylglycerol plus 1(3)-oleoylglycerol plus 1(3)-
cis-vaccenoylglycerol (Fig. 3D) were generated during the in-
cubation in the presence of Ca2 (3.5- and 2.5-fold, and 58.6
and 26.2 pmol/mg protein increases over the levels at time 0,
respectively), while the increases were less pronounced com-
pared with that of 2-arachidonoylglycerol. We also con¢rmed
that the amounts of several other minor species, such as
2-docosahexaenoylglycerol and 1(3)-docosahexaenoylglycerol,
increased to some extent during the incubation in the presence
of Ca2 (Fig. 3E,F). Importantly, the addition of EGTA in-
stead of CaCl2 reduced the generation of 2-arachidonoyl-
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Table 1
Molecular species compositions of monoacylglycerols obtained from various rat tissues
Monoacylglycerol
species
Brain Liver Spleen Lung Kidney Plasma
nmol/g
tissue
(%) nmol/g
tissue
(%) nmol/g
tissue
(%) nmol/g
tissue
(%) nmol/g
tissue
(%) nmol/ml (%)
1(3)-14:0+1(3)-16:1(n-7) 0.00 þ 0.00 (0.0) 0.03 þ 0.06 (0.4) 0.00 þ 0.00 (0.0) 0.04 þ 0.08 (0.5) 0.01 þ 0.02 (0.2) 0.012 þ 0.008 (0.7)
2-14:0+2-16:1(n-7)+
1(3)-18:2(n-6)
0.01 þ 0.01 (0.1) 0.69 þ 1.08 (8.6) 0.32 þ 0.16 (4.7) 0.34 þ 0.32 (4.3) 0.12 þ 0.11 (2.3) 0.258 þ 0.147 (15.7)
1(3)-16:0+1(3)-18:1
(n-7,n-9)
1.64 þ 0.21 (15.3) 2.08 þ 1.38 (26.0) 1.25 þ 0.15 (18.4) 3.90 þ 1.45 (49.4) 1.86 þ 0.74 (34.9) 0.288 þ 0.118 (17.5)
2-16:0+2-18:1(n-7,n-9) 3.66 þ 0.34 (34.0) 1.66 þ 0.92 (20.8) 2.50 þ 1.13 (36.8) 1.53 þ 0.40 (19.4) 1.44 þ 0.18 (27.0) 0.540 þ 0.212 (32.8)
1(3)-18:0 0.18 þ 0.23 (1.7) 0.14 þ 0.25 (1.8) 0.27 þ 0.05 (4.0) 0.14 þ 0.31 (1.8) 0.08 þ 0.11 (1.5) 0.034 þ 0.076 (2.1)
2-18:2(n-6) 0.05 þ 0.04 (0.5) 1.27 þ 1.24 (15.9) 0.60 þ 0.18 (8.8) 0.46 þ 0.37 (5.8) 0.26 þ 0.10 (4.9) 0.500 þ 0.250 (30.3)
1(3)-20:4(n-6) 1.39 þ 0.49 (12.9) 0.55 þ 0.56 (6.9) 0.63 þ 0.49 (9.3) 0.59 þ 0.30 (7.5) 0.48 þ 0.20 (9.0) 0.004 þ 0.005 (0.2)
2-20:4(n-6) 3.36 þ 1.34 (31.2) 1.15 þ 0.45 (14.4) 1.17 þ 0.55 (17.2) 0.78 þ 0.23 (9.9) 0.98 þ 0.46 (18.4) 0.012 þ 0.004 (0.7)
1(3)-22:6(n-3) 0.21 þ 0.16 (2.0) 0.17 þ 0.20 (2.1) 0.03 þ 0.03 (0.4) 0.07 þ 0.06 (0.9) 0.04 þ 0.03 (0.7) 0.000 þ 0.000 (0.0)
2-22:6(n-3) 0.25 þ 0.17 (2.3) 0.25 þ 0.12 (3.1) 0.03 þ 0.02 (0.4) 0.04 þ 0.03 (0.5) 0.06 þ 0.03 (1.1) 0.000 þ 0.000 (0.0)
Total 10.75 þ 1.87 (100.0) 7.99 þ 5.37 (100.0) 6.80 þ 1.05 (100.0) 7.89 þ 2.24 (100.0) 5.33 þ 1.29 (100.0) 1.648 þ 0.701 (100.0)
Monoacylglycerols were analyzed as dianthroyl derivatives as described in Section 2. The data are the means þ S.D. of ¢ve determinations.
Fig. 2. Electron-impact mass spectra of TMS derivatives of arachi-
donoylglycerols obtained from rat brain. A: 2-Arachidonoylglycerol.
B: 1(3)-Arachidonoylglycerol.
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glycerol markedly (Fig. 3A). However, noticeably, the gener-
ation of 2-arachidonoylglycerol was not totally abolished even
in the presence of EGTA, suggesting that a mechanism for
Ca2-independent generation of 2-arachidonoylglycerol exists
besides that for Ca2-dependent generation in this tissue.
4. Discussion
This is the ¢rst detailed comparative study on the molecular
species of monoacylglycerols in various mammalian tissues.
The results obtained here clearly indicate that 2-arachidonoyl-
glycerol is one of the major species of monoacylglycerols in
several rat tissues, especially the brain. In a previous study, we
found that rat brain contains a high level of arachidonoylglyc-
erol [16], yet no information has been presented so far con-
cerning other tissues. Stella et al. [21] also demonstrated that
2-arachidonoylglycerol is present in rat brain, while they did
not describe either other molecular species in brain or mono-
acylglycerols in other tissues. Therefore, the present data con-
cerning the molecular species compositions of monoacylglyc-
erols in various rat tissues are of importance, highlighting the
possible physiological signi¢cance of 2-arachidonoylglycerol
in mammalian tissues.
Among the data shown here, the abundance of 2-arachido-
noylglycerol in the monoacylglycerol fraction in brain (Table
1) is particularly noteworthy in view of the fact that various
species of monoacylglycerols other than 2-arachidonoylglycer-
ol do not exhibit appreciable cannabimimetic activity toward
neuronal cells [18], and in view of the fact that the cannabi-
noid receptor is highly abundant in the brain [24]. Indeed, the
level of the cannabinoid receptor(s) in the brain is known to
be almost the same as that of glutamic acid receptors or Q-
aminobutyric acid (GABA) receptors [24], suggesting that the
endogenous cannabinoid receptor ligand(s) is a rather com-
mon molecule and is present abundantly in this tissue. Appar-
ently, 2-arachidonoylglycerol, but not anandamide, ful¢lls this
requirement. Possibly, 2-arachidonoylglycerol is a physiologi-
cally important molecule, like glutamic acid or GABA, in the
brain. It should also be noted that 2-arachidonoylglycerol is
present not only in brain but also in spleen, kidney and lung
(Table 1). Cannabinoid receptors have been reported to exist
in these tissues besides in brain [24^26]; 2-arachidonoylglycer-
ol may play some important physiological roles in these tis-
sues as well.
Obviously, GC-MS analysis is essential and indispensable
for verifying the structures of monoacylglycerols. Several in-
vestigators have developed methods for GC-MS analyses of
monoacylglycerols [27^30]. However, not much attention has
been directed toward monoacylglycerols actually present in
mammalian tissues. In a recent report, Stella et al. [21] pre-
sented the GC-MS spectrum of the TMS derivative of
2-arachidonoylglycerol obtained from rat brain, although
the mass spectra for other species of monoacylglycerols were
not given. They attributed [M-71] to the loss of the pentyl
radical. However, we detected [M-71] in other species of
2-monoacylglycerols, such as 2-palmitoylglycerol, similar to
2-arachidonoylglycerol (data not shown). It is possible, there-
fore, that the formation of [M-71] is not due to cleavage at
the double bond. We assume that the structure of [M-71] is
[RCOH+O-Si(CH3)2+O-Si(CH3)3] based on the results of
elementary analyses of [M-71] involving high resolution
mass spectrometry (Tokumura, A. and Sugiura, T., unpub-
lished results).
One of the most important ¢ndings shown here is the ex-
plosive generation of 2-arachidonoylglycerol in a rat brain
homogenate during incubation, especially in the presence of
Ca2 (Fig. 3). This provides clear evidence that rat brain
contains both the substrates and enzyme activities responsible
for the generation of 2-arachidonoylglycerol. We assume that
most of 1(3)-arachidonoylglycerol was formed from 2-arach-
idonoylglycerol by isomerization. It should be noted that the
amount of 2-arachidonoylglycerol generated upon incubation
in the presence of Ca2 exceeded those of other species of
monoacylglycerols (Fig. 3), indicating that Ca2 stimulated
the generation of 2-arachidonoylglycerol preferentially. Calci-
um ionophore-dependent generation of 2-arachidonoylglycer-
ol in cultured neuronal cells was recently reported by several
investigators [21,31]. Importantly, the generation of 2-arach-
idonoylglycerol proceeded to some extent even in the presence
of EGTA (Fig. 3). Possible reasons for this may be as follows:
(i) There are at least two separate pathways (Ca2-dependent
and -independent ones) responsible for the generation of
2-arachidonoylglycerol. (ii) The enzyme activities responsible
for the generation of 2-arachidonoylglycerol do not require
the presence of Ca2 but are stimulated by Ca2. Previously,
we pointed out that 2-arachidonoylglycerol can be formed
through several metabolic pathways, such as the hydrolysis
of arachidonic acid-containing diacylglycerol, and the hydrol-
ysis of arachidonic acid-containing 2-acyl lysophospholipids,
derived from membrane phospholipids, by speci¢c phospholi-
pase C [16]. It is noteworthy that some of the enzyme activ-
ities involved in these pathways are known to be regulated by
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Fig. 3. E¡ects of Ca2 on the generation of 2-arachidonoylglycerol
and other molecular species of monoacylglycerols in a rat brain ho-
mogenate. A: 2-Arachidonoylglycerol. B: 1(3)-Arachidonoylglycerol.
C: 2-Palmitoylglycerol plus 2-oleoylglycerol plus 2-cis-vaccenoyl-
glycerol. D: 1(3)-Palmitoylglycerol plus 1(3)-oleoylglycerol plus 1(3)-
cis-vaccenoylglycerol. E: 2-Docosahexaenoylglycerol. F: 1(3)-Doco-
sahexaenoylglycerol. Open bars, before incubation; closed bars,
after 5 min incubation in the presence of 1.3 mM CaCl2 ; hatched
bars, after 5 min incubation in the presence of 2.5 mM EGTA. The
data are the means þ S.D. of four determinations. *P6 0.05,
**P6 0.01, ***P6 0.001 (compared to the control (before incuba-
tion)) (Student’s t-test).
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Ca2. In any case, the mechanisms underlying the generation
of 2-arachidonoylglycerol appear to be rather complicated,
and further detailed studies are necessary to elucidate the
mechanisms underlying the Ca2-dependent and -independent
generation of 2-arachidonoylglycerol in this tissue.
Ca2-dependent or -stimulated generation of 2-arachido-
noylglycerol is particularly noticeable in view of the fact
that various types of neurotransmitters such as glutamic
acid induce elevation of the intracellular free Ca2 concentra-
tion in postsynapses. We previously demonstrated that
2-arachidonoylglycerol reduces depolarization-induced eleva-
tion of the intracellular free Ca2 concentration in NG108-15
cells [32]. Stella et al. [21] also demonstrated that 2-arachido-
noylglycerol reduces LTP in rat hippocampal slices, in which
elevation of the postsynaptic free Ca2 concentration is cru-
cially important. Thus, 2-arachidonoylglycerol generated by
activated neuronal cells may play an important role in stabi-
lizing these cells following stimulation, leading to negative
feedback control of neurotransmission. Such a mechanism
should be of great physiological signi¢cance, because sus-
tained elevation of Ca2 is deleterious and toxic to neuronal
cells. So far, not much attention has been paid to the phys-
iological signi¢cance of monoacylglycerols. The physiological
roles, dynamics and metabolism of 2-arachidonoylglycerol, a
cannabimimetic monoacylglycerol, in the nervous system as
well as in other systems will be clari¢ed in the near future.
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